Washtenaw County Employees' Retirement System v. Walgreen Co.

District Court, N.D. Illinois·Decided November 15, 2019·No. 1:15-cv-03187·Unknown

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION WASHTENAW COUNTY EMPLOYEES’ ) RETIREMENT SYSTEM, Individually and ) on Behalf of All Others Similarly Situated, ) ) Case No. 15 C 3187 Plaintiffs, ) ) District Judge: Sharon Johnson Coleman v. ) ) Magistrate Judge: Gabriel A. Fuentes WALGREEN CO., GREGORY D. ) WASSON, and WADE D. MIQUELON, _) ) Defendants. ) MEMORANDUM OPINION AND ORDER Lead Plaintiff Industriens Pensionsforsikring, A/S (“Plaintiffs”)! has renewed its Motion To Compel Defendant Wade D. Miquelon To Produce Documents Provided to the Securities and Exchange Commission (D.E. 260, “Motion to Compel”). The documents consist of three PowerPoint presentations dated April 18, May 2, and June 7, 2018, and one “white paper” dated June 4, 2018 (collectively, “the Miquelon Rule 408 SEC Materials”), submitted to the SEC during discussions leading to a September 2018 settlement of the SEC’s investigation into Miquelon and the other two defendants in this case, Walgreen Co. (“Walgreens”) and Gregory D. Wasson. Miquelon has submitted the Miquelon Rule 408 SEC Materials for in camera review.? This matter

* This Court will refer to movant Industriens Pensionforsikring A/S, which was appointed by the district court to serve as lead class plaintiff, as “Plaintiffs.” (See D.E. 244 n.1.) ? The parties recite a tortured history of supposed Local Rule 37.2 compliance going back to a now stale in-person conference in June 2019 and a long series of discovery correspondence afterwards. Motion to Compel at 5; Response, Exs. |~2. The Court could determine from this collage of letters and emails that on October 11, 2019, Plaintiffs communicated that they would file their motion to compel and state that Miquelon was refusing to submit the Miquelon Rule 408 SEC Materials for in camera review, whereupon counsel for Miquelon sent Plaintiffs an email saying he would make such an in camera submission, and then nothing in the record shows whether anything else happened (by way of good-faith efforts to resolve the dispute) before Plaintiffs abruptly filed the Motion to Compel on October 25, three days before Defendants answered the Complaint on October 28. Miquelon submitted the Miquelon Rule 408 SEC Materials for in camera review on October 29. The Court has determined that

is before the magistrate judge on the district court’s referral for discovery supervision. (D.E. 147.) For the reasons stated below, the Court denies the Motion to Compel. I, Background The underlying facts and allegations in this matter are set forth in detail in Judge Sharon Johnson Coleman’s recent Memorandum Opinion (D.E. 244) granting in part and denying in part the defendants’ motion to dismiss under Rule 12(b)(6) and need not be repeated in full here. In short, Plaintiffs have brought a securities fraud class action lawsuit against Walgreens, its former Chief Executive Officer Gregory D. Wasson (“Wasson”), and Miquelon, its former chief financial officer (collectively, “Defendants”) under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Plaintiffs’ allegations relate to Walgreens’s public statements concerning the expected benefits of a 2012 merger with Alliance Boots GmbH, in the form of a goal, for fiscal year 2016, of between $9 billion and $9.5 billion (“the FY 2016 EBIT Goal”) in adjusted earnings before interest and taxes (“EBIT”). Jd. at 2. Plaintiffs allege that Walgreens had become aware that earnings would fall short of that goal, in large part due to a significant level of generic drug price inflation and a phenomenon known as “reimbursement pressure,” by the class period of March to August 2014 but continued to make statements or omissions that downplayed the risk of not achieving the FY 2016 EBIT Goal. Id. “Despite Defendants’ actual knowledge of the Company’s massive FY16 EBIT shortfall and the company-specific reasons underlying it (i.e., generic drug price inflation combined with unfavorable reimbursement contracts), Defendants concealed these material facts from investors and continued to tout the $9 to $9.5 billion in FY16 EBIT.” Redacted First Amended Consolidated

notwithstanding the questionable adherence to Local Rule 37.2 and Rule 37(a}(1) of the Federal Rules of Civil Procedure, the submission of the withheld Rule 408 materials in camera places this Court in a position to resolve this scovery dispute in a way that promotes a just, speedy, and inexpensive determination of the matter. See Fed. R. Civ.

Class Complaint (D.E. 199, “Compiaint”) J 9. Defendant Miquelon, whose 2018 submissions to the SEC are sought in the Motion to Compel, was chief financial officer of Walgreens during the class period up to August 4, 2014. Defendant Miquelon’s Amended Answer to Consolidated Class Action Complaint (D.E. 87) § 38. Walgreens asserts that it began negotiating a settlement with the SEC in September 2017. Walgreens’s Statement Regarding Plaintiff's Motion to Compel (D.E. 273) at 1; Miquelon has represented that in mid-December 2017, the SEC proposed settlement terms to Miquelon’s attorneys.? Defendant Wade D. Miquelon’s Response to Lead Plaintiff's Motion To Compel Defendant Wade D. Miquelon To Produce Documents Provided to the Securities and Exchange Commission (D.E. 272, “Response”) at 1. On September 28, 2018, the SEC concluded its three- year investigation by announcing a settlement that called for Walgreens to pay a $34.5 million penalty and included a cease-and-desist order, along with a penalty of $160,000 for Miquelon and Wasson, without an admission or denial by Walgreens, Miquelon, or Wasson of the SEC’s findings that they had misled investors about the FY 2017 EBIT Goal. SEC Press Release 2018-220, “SEC Charges Walgreens and Two Former Executives With Misleading Investors About Forecasted Earnings Goal” (Sept. 28, 2018) (https://www.sec.gov/news/press-release/2018-220); Motion to Compel, Ex. A. The portion of the SEC investigation leading to that settlement was known as “Phase II.” On November 14, 2018, this Court, per then-Magistrate Judge Rowland, ordered defendants to produce certain exhibits and core documents submitted to the SEC during Phase II (Phase I being irrelevant to this matter), except for materials concerning solely international and/or non-pharmacy matters. (D.E. 171.) The November 2018 ruling on that separate, earlier motion to compel did not > Plaintiffs stated at oral argument on November 12, 2019, that they lacked sufficient information to dispute these assertions.

concern the Miquelon Rule 408 SEC Materials. Judge Rowland by then already had concluded that “documents addressing the impact of generic inflation and/or reimbursement pressure on the FY 2016 EBIT Goal are relevant for discovery” and that Walgreens would have to produce them, whether they address the impact of those two issues either in 2013-14 or through fiscal year 2016. (D.E. 167.) Those conclusions are unaffected by Judge Coleman’s ruling on Walgreens’s motion to dismiss the Complaint, as she found nonactionable only Plaintiffs’ claim stemming from statements made at the April 30, 2014, Barclay’s conference by Rick Hans of Walgreens. (D.E. 244 at 12.) In the end, this Court must consider whether the Miquelon Rule 408 SEC Materials are within the scope of permissible discovery as relevant to a claim or defense and proportional to the needs of the case. Fed. R. Civ. P. 26(b)(1). The Motion to Compel argues that the purported inadmissibility of the Miquelon Rule 408 SEC Materials as settlement communications does not render them non-discoverable in the litigation. Motion to Compel at 3.

Free access — add to your briefcase to read the full text and ask questions with AI

Washtenaw County Employees' Retirement System v. Walgreen Co., (N.D. Ill. 2019).

Washtenaw County Employees' Retirement System v. Walgreen Co. (Washtenaw County Employees' Retirement System v. Walgreen Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Emil Perzinski v. Chevron Chemical Company
503 F.2d 654 (Seventh Circuit, 1974)
Morley-Murphy Co. v. Zenith Electronics Corp.
142 F.3d 373 (Seventh Circuit, 1998)
Zurich American Insurance Company v. Watts Industries
417 F.3d 682 (Seventh Circuit, 2005)
Morley-Murphy Co. v. Zenith Electronics Corp.
910 F. Supp. 450 (W.D. Wisconsin, 1996)
Pfizer Inc. v. Apotex Inc.
731 F. Supp. 2d 754 (N.D. Illinois, 2010)
Quad/Graphics, Inc. v. Fass
724 F.2d 1230 (Seventh Circuit, 1983)
Vardon Golf Co. v. BBMG Golf Ltd.
156 F.R.D. 641 (N.D. Illinois, 1994)